Comparative Pharmacology
Head-to-head clinical analysis: AMOXAPINE versus ANAFRANIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXAPINE versus ANAFRANIL.
AMOXAPINE vs ANAFRANIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
None Documented
None Documented
Clinical Note
moderateAmoxapine + Budesonide
"The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone furoate
"The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate."
Clinical Note
moderateParent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
Amoxapine + Desmopressin
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin."